Sugi Predict

Sugi Predict / Compounds / SCHEMBL2658692

SCHEMBL2658692

SCHEMBL2658692

COC(=O)c1ccc(CC(C(=O)O)c2ccc(CC(C)C)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 4/20 0.60
▸ PTGS2 P35354 4/20 0.60
▸ CXCR1 P25024 3/20 0.54
▸ CXCR2 P25025 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ AKR1C3 P42330 2/20 0.54
▸ ESR1 P03372 2/20 0.54
▸ ALOX5 P09917 2/20 0.54
▸ ALB P02768 1/20 0.54
▸ RARB P10826 1/20 0.54
▸ ADRB3 P13945 1/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ HTR2A P28223 1/20 0.54
▸ NR1I3 Q14994 1/20 0.54
▸ SLC22A6 Q4U2R8 1/20 0.54
▸ CXCL8 P10145 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ AKR1C2 P52895 1/20 0.54
▸ BLM P54132 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657856 0.89 ESR1 (0.64) PTGS1PTGS2LMNACYP2C9ESR1
SCHEMBL13494578 0.89 ESR1 (0.49) PTGS1PTGS2CYP2C9ESR1TSHR
SCHEMBL1918994 0.87 ESR1 (0.48) PTGS1PTGS2LMNACYP2C9ESR1
SCHEMBL765010 0.86 LOXL2 (0.61) PTGS1PTGS2CXCR1CXCR2LMNA
SCHEMBL2658400 0.85 CA1 (0.56) ESR1ESR2LOXL2
SCHEMBL2659063 0.85 CA1 (0.56) ESR1ESR2LOXL2
SCHEMBL2658399 0.85 CA1 (0.56) ESR1ESR2LOXL2
SCHEMBL25146751 0.82 LOXL2 (0.56) CXCR1CXCR2LOXL2MAPTCYP4A11
SCHEMBL2662483 0.80 ESR1 (0.41) PTGS1PTGS2LMNACYP2C9ESR1
SCHEMBL2647042 0.80 BCL2L1 (0.49) ESR1ESR2LOXL2EPHX1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 — — US disclosed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 — — US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 — — US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 — — US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 — — EP disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
EP-2129654-B1 ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2014-05-28 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-8710236-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2014-04-29 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 — — EP disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 PTGS1 1893/4885PTGS2 2257/4885CXCR1 212/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 PTGS1 2208/4885PTGS2 2534/4885CXCR1 210/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 PTGS1 1912/4885PTGS2 2305/4885CXCR1 208/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 PTGS1 1912/4885PTGS2 2305/4885CXCR1 208/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 PTGS1 1912/4885PTGS2 2305/4885CXCR1 208/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 PTGS1 2191/4885PTGS2 2521/4885CXCR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.